NewAmsterdam Pharma (NAMS) Cash from Operations (2023 - 2026)
NewAmsterdam Pharma (NAMS) posted Cash from Operations of 30604000.0 for Q1 2026, up 25.13% sequentially from 40875000.0 in Q4 2025, and up 16.08% YoY from 26364610.03 in Q1 2025.
Powered by 
Analysis
NewAmsterdam Pharma (NAMS) Cash from Operations (2023 - 2026) Analysis & Trends
NewAmsterdam Pharma has reported Cash from Operations for 4 years, with the latest figure at 30604000.0 in Q1 2026.
- Quarterly Cash from Operations rose 16.08% year-over-year to 30604000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 141919000.0 (down 1.06% YoY) and the FY2025 annual result came in at 147783000.0, up 6.8% from the prior year.
- Cash from Operations climbed to 30604000.0 in Q1 2026 per NAMS's latest filing, from 40875000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 12502000.0 in Q3 2024 and troughed at 54602000.0 in Q1 2024.
- A 4-year average of 36782230.77 and a median of 36468000.0 in 2025 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2024 and 2025: Cash from Operations soared 73.39% in 2024, then sank 162.11% in 2025.
- Over 4 years, Cash from Operations stood at 33074000.0 in 2023, then dropped by 13.32% to 37481000.0 in 2024, then declined by 9.06% to 40875000.0 in 2025, then climbed by 25.13% to 30604000.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 30604000.0, 40875000.0, and 32769000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -88.83 Mn |
| 10 | NewAmsterdam Pharma | 3.13 Bn | 3.13 Bn | - | -39.21 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -39.21 Mn |
| Mar 31, 2026 | -30.60 Mn |
| Dec 31, 2025 | -40.88 Mn |
| Sep 30, 2025 | -32.77 Mn |
| Jun 30, 2025 | -37.67 Mn |
| Mar 31, 2025 | -36.47 Mn |
| Dec 31, 2024 | -37.48 Mn |
| Sep 30, 2024 | -12.50 Mn |
| Jun 30, 2024 | -53.98 Mn |
| Mar 31, 2024 | -54.60 Mn |
| Dec 31, 2023 | -33.07 Mn |
| Sep 30, 2023 | -46.98 Mn |
| Jun 30, 2023 | -29.31 Mn |
| Mar 31, 2023 | -31.86 Mn |